Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Camila L. Ferreira is active.

Publication


Featured researches published by Camila L. Ferreira.


Journal of Psychiatric Research | 2010

Effects of mood stabilizers on mitochondrial respiratory chain activity in brain of rats treated with d-amphetamine.

Samira S. Valvassori; Gislaine T. Rezin; Camila L. Ferreira; Morgana Moretti; Cinara L. Gonçalves; Mariana R. Cardoso; Emilio L. Streck; Flávio Kapczinski; João Quevedo

Bipolar disorder (BD) is a devastating major mental illness associated with high rates of suicide and work loss. There is an emerging body of data suggesting that bipolar disorder is associated with mitochondrial dysfunction. In this context, the present study aims to investigate the effects of mood stabilizers lithium (Li) and valproate (VPT) on mitochondrial respiratory chain activity in brain of rats undergoing treatment with the pro-manic agent d-AMPH d-amphetamine (d-AMPH). In the reversal treatment, Wistar rats were first given d-AMPH or saline for 14 days, and then, between days 8 and 14, rats were treated with Li, VPA or saline (Sal). In the prevention treatment, rats were pretreated with Li, VPA or Sal. Locomotor behavior was assessed using the open-field task and mitochondrial chain activity complexes I, II, III and IV were measured in brain structures (hippocampus, striatum and prefrontal). Li and VPA reversed and prevented d-AMPH-induced hyperactivity. In both experiments, d-AMPH inhibited mitochondrial respiratory chain activity in all analyzed structures. In the reversal treatment, VPA reversed d-AMPH-induced dysfunction in all brain regions analyzed. In the prevention experiment, the effects of Li and VPA on d-AMPH-induced mitochondrial dysfunction were dependent on the brain region analyzed. These findings suggested that dopamine can be an important link for the mitochondrial dysfunction seen in BD and, Li and VPA exert protective effects against this d-AMPH-induced mitochondrial dysfunction, but this effect varies depending on the brain region and the treatment regimen.


Journal of Psychiatric Research | 2011

Lithium and valproate modulate antioxidant enzymes and prevent ouabain-induced oxidative damage in an animal model of mania

Luciano K. Jornada; Samira S. Valvassori; Amanda V. Steckert; Morgana Moretti; Francielle Mina; Camila L. Ferreira; Camila O. Arent; Felipe Dal-Pizzol; João Quevedo

In this study, we assessed the oxidative stress parameters in rats submitted to an animal model of mania induced by ouabain (OUA), which included the use of lithium (Li) and valproate (VPA). Li and VPA treatment reversed and prevented the OUA-induced damage in these structures, however, this effect varies depending on the brain region and treatment regimen. Moreover, the activity of the antioxidant enzymes, namely, superoxide dismutase (SOD) and catalase (CAT) was found to be increased and decreased, respectively, in the brain of OUA-administered rats. Li and VPA modulated SOD and CAT activities in OUA-subjected rats in both experimental models. Our results support the notion that Li and VPA exert antioxidant-like properties in the brain of rats submitted to animal model of mania induced by ouabain.


Journal of Psychiatric Research | 2010

Effects of mood stabilizers on hippocampus and amygdala BDNF levels in an animal model of mania induced by ouabain

Luciano K. Jornada; Morgana Moretti; Samira S. Valvassori; Camila L. Ferreira; Peterson Teodoro Padilha; Camila O. Arent; Gabriel Rodrigo Fries; Flávio Kapczinski; João Quevedo

There is a body of evidence suggesting that BDNF is involved in bipolar disorder (BD) pathogenesis. Intracerebroventricular (ICV) injection of ouabain (OUA), a specific Na(+)/K(+) ATPase inhibitor, induces hyperlocomotion in rats, and has been used as an animal model of mania. The present study aims to investigate the effects of the lithium (Li) and valproate (VPT) in an animal model of mania induced by ouabain. In the reversal model, animals received a single ICV injection of OUA or cerebrospinal fluid (aCSF). From the day following the ICV injection, the rats were treated for 6 days with intraperitoneal (IP) injections of saline (SAL), Li or VPT twice a day. In the maintenance treatment (prevention model), the rats received IP injections of Li, VPT, or SAL twice a day for 12 days. In the 7th day of treatment the animals received a single ICV injection of either OUA or aCSF. After the ICV injection, the treatment with the mood stabilizers continued for more 6 days. Locomotor activity was measured using the open-field test and BDNF levels were measured in rat hippocampus and amygdala by sandwich-ELISA. Li and VPT reversed OUA-related hyperactive behavior in the open-field test in both experiments. OUA decreased BDNF levels in first and second experiments in hippocampus and amygdala and Li treatment, but not VPT reversed and prevented the impairment in BDNF expression after OUA administration in these cerebral areas. Our results suggest that the present model fulfills adequate face, construct and predictive validity as an animal model of mania.


Behavioural Pharmacology | 2011

Behavioral and neurochemical effects of sodium butyrate in an animal model of mania.

Morgana Moretti; Samira S. Valvassori; Roger B. Varela; Camila L. Ferreira; Natália Rochi; Joana Benedet; Giselli Scaini; Flávio Kapczinski; Emilio L. Streck; Alexandra I. Zugno; João Quevedo

The present study investigated the effect of the histone deacetylase inhibitor, sodium butyrate (SB), on locomotor behavior and on mitochondrial respiratory-chain complexes activity in the brain of rats subjected to an animal model of mania induced by d-amphetamine (d-AMPH). In the reversal treatment, Wistar rats were first treated with d-AMPH or saline (Sal) for 14 days. Thereafter, between days 8 and 14, rats were administered SB or Sal. In the prevention treatment, rats were treated with SB or Sal for 14 days and received d-AMPH or Sal between days 8 and 14. The d-AMPH treatment increased locomotor behavior in Sal-treated rats under reversion and prevention treatment, and SB reversed and prevented d-AMPH-related hyperactivity. Moreover, d-AMPH decreased the activity of mitochondrial respiratory-chain complexes in Sal-treated rats in the prefrontal cortex, hippocampus, striatum, and amygdala in both experiments, and SB was able to reverse and prevent this impairment. The present study suggests that the mechanism of action of SB involves induction of mitochondrial function in parallel with behavioral changes, reinforcing the need for more studies on histone deacetylase inhibitors as a possible target for new medications for bipolar disorder treatment.


International Journal of Developmental Neuroscience | 2010

Intracerebroventricular ouabain administration induces oxidative stress in the rat brain.

Rafael E. Riegel; Samira S. Valvassori; Morgana Moretti; Camila L. Ferreira; Amanda V. Steckert; Bruna de Souza; Felipe Dal-Pizzol; João Quevedo

Intracerebroventricular (ICV) injection of ouabain (a potent Na+/K+‐ATPase inhibitor) in rats resulted in manic‐like effects. There is an emerging body of data indicating that major neuropsychiatric disorders, such as bipolar disorder and schizophrenia, are associated with increased oxidative stress. In this study, we investigated the effects of ICV ouabain injection on oxidative stress parameters in total tissue of rat brain. Our findings demonstrated that ICV injection increased thiobarbituric acid reactive species levels and protein carbonyl generation in the prefrontal cortex and hippocampus of rats. Moreover, the activity of the antioxidants enzymes catalase and superoxide dismutase was altered in several areas of the rat brain and cerebrospinal fluid of ICV ouabain‐subjected rats. These results showed that Na+/K+‐ATPase inhibition can lead to oxidative stress in the brain of rats.


Revista Brasileira de Psiquiatria | 2013

Histone deacetylase activity and brain-derived neurotrophic factor (BDNF) levels in a pharmacological model of mania

Laura Stertz; Gabriel Rodrigo Fries; Bianca Wollenhaupt de Aguiar; Bianca Pfaffenseller; Samira S. Valvassori; Carolina Gubert; Camila L. Ferreira; Morgana Moretti; Keila Maria Mendes Ceresér; Márcia Kauer-Sant'Anna; João Quevedo; Flávio Kapczinski

OBJECTIVE In the present study, we aimed to examine the effects of repeated D-amphetamine (AMPH) exposure, a well-accepted animal model of acute mania in bipolar disorder (BD), and histone deacetylase (HDAC) inhibitors on locomotor behavior and HDAC activity in the prefrontal cortex (PFC) and peripheral blood mononuclear cells (PBMCs) of rats. Moreover, we aimed to assess brain-derived neurotrophic factor (BDNF) protein and mRNA levels in these samples. METHODS We treated adult male Wistar rats with 2 mg/kg AMPH or saline intraperitoneally for 14 days. Between the 8th and 14th days, rats also received 47.5 mg/kg lithium (Li), 200 mg/kg sodium valproate (VPT), 2 mg/kg sodium butyrate (SB), or saline. We evaluated locomotor activity in the open-field task and assessed HDAC activity in the PFC and PBMCs, and BDNF levels in the PFC and plasma. RESULTS AMPH significantly increased locomotor activity, which was reversed by all drugs. This hyperactivity was associated with increased HDAC activity in the PFC, which was partially reversed by Li, VPT, and SB. No differences were found in BDNF levels. CONCLUSION Repeated AMPH administration increases HDAC activity in the PFC without altering BDNF levels. The partial reversal of HDAC increase by Li, VPT, and SB may account for their ability to reverse AMPH-induced hyperactivity.


Psychiatry Research-neuroimaging | 2012

Effects of lithium and valproate on oxidative stress and behavioral changes induced by administration of m-AMPH

Dayane D. da-Rosa; Samira S. Valvassori; Amanda V. Steckert; Felipe Ornell; Camila L. Ferreira; Jéssica Lopes-Borges; Roger B. Varela; Felipe Dal-Pizzol; Monica L. Andersen; João Quevedo

In the last years our research group has studied and validated the animal model of mania induced by dextroamphetamine (d-AMPH). Considering the lack of animal models of mania reported in the literature; this study evaluated the possibilities to validate the animal model induced by methamphetamine (m-AMPH). Then, we evaluated the effects of lithium (Li), valproate (VPA) on the behavior and parameters of oxidative damage in rat brain after administration of m-AMPH. In the prevention treatment, Wistar rats were pretreated with Li, VPA or saline (Sal) for 14 days, and then, between days 8 and 14, rats were treated with m-AMPH (1, 0.5 or 0.25 mg/kg) or Sal. In the reversal treatment, rats were first given m-AMPH (0.25 mg/kg) or Sal. Locomotor behavior was assessed using the open-field task and parameters of oxidative damage were measured in brain structures. Our results show that the hyperactivity was prevented and reverted by Li and VPA only when m-AMPH was administered in the dose of 0.25mg/kg. In addition, the m-AMPH in all doses administrated induced oxidative damage in both structures tested in two models. Li and VPA reversed and prevented this impairment, however in a way dependent of cerebral area, the dose of m-AMPH and technique.


Revista De Psiquiatria Clinica | 2012

Decreased BDNF levels in amygdala and hippocampus after intracerebroventricular administration of ouabain

Luciano K. Jornada; Samira S. Valvassori; Wilson R. Resende; Morgana Moretti; Camila L. Ferreira; Gabriel Rodrigo Fries; Flávio Kapczinski; João Quevedo

OBJETIVO: O presente estudo tem como objetivo investigar os efeitos da injecao intracerebroventricular de ouabaina sobre os niveis de BDNF na amigdala e no hipocampo de ratos Wistar. METODOS: Os animais receberam uma unica injecao intracerebroventricular de ouabaina (10-3 and 10-2 M) ou fluido cerebroespinhal artificial e, imediatamente, 3h, 24h ou sete dias apos a injecao, os niveis de BDNF foram mensurados na amigdala e hipocampo dos ratos por ELISA sandwich (n = 8 animais por grupo). RESULTADOS: Quando avaliados imediatamente apos a injecao, 3h ou 24h, ouabaina nas doses 10-2 e 10-3 M nao alterou os niveis de BDNF em ambas as estruturas avaliadas. Entretanto, quando avaliados sete dias apos a injecao, ouabaina nas doses 10-2 e 10-3 M mostrou uma significante reducao nos niveis de BDNF em amigdala e hipocampo. CONCLUSAO: Em conclusao, propoe-se que a administracao de ouabaina diminuiu os niveis de BDNF em amigdala e hipocampo quando avaliados sete dias apos a injecao, suportando a hipotese da participacao da Na/K ATPase no transtorno bipolar.


Neuroscience Letters | 2010

DNA damage after intracerebroventricular injection of ouabain in rats.

Luciano K. Jornada; Samira S. Valvassori; Camila O. Arent; Daniela Dimer Leffa; Adriani A. Damiani; Giana Hainzenreder; Camila L. Ferreira; Morgana Moretti; Vanessa Moraes de Andrade; João Quevedo

There is an emerging body of data suggesting that bipolar disorder is associated with DNA damage. Intracerebroventricular (i.c.v.) administration of ouabain in rats results in manic-like alterations. We evaluated DNA damage of peripheral blood, cerebrospinal fluid and hippocampus of rats after i.c.v. ouabain injection. Ouabain-induced hyperlocomotion was examined in an open field. Additionally, we used single cell gel electrophoresis (comet assay) to measure early transient damage in cerebrospinal fluid (CSF), hippocampus and blood; and the micronucleus test to measure persistent damage in total blood samples of rats after ouabain administration. Our findings demonstrated that ouabain induced hyperlocomotion in rats, and this response remained up to 7 days following a single i.c.v. injection. In addition, we observed that the persistent increase in the rat spontaneous locomotion is associated with increased hippocampal and peripheral index of early DNA damage in rats. No significant alterations were observed in the micronucleus frequency in total blood samples of the rats after the ouabain i.c.v. injection. These results suggest that ouabain may induce peripheral and central early DNA damage, but this early damage may be repaired.


Molecular Neurobiology | 2011

Neuroanatomical profile of antimaniac effects of histone deacetylases inhibitors.

Camila O. Arent; Samira S. Valvassori; Gabriel Rodrigo Fries; Laura Stertz; Camila L. Ferreira; Jéssica Lopes-Borges; Edemilson Mariot; Roger B. Varela; Felipe Ornell; Flávio Kapczinski; Monica L. Andersen; João Quevedo

Collaboration


Dive into the Camila L. Ferreira's collaboration.

Top Co-Authors

Avatar

Samira S. Valvassori

Universidade do Extremo Sul Catarinense

View shared research outputs
Top Co-Authors

Avatar

João Quevedo

University of Texas Health Science Center at Houston

View shared research outputs
Top Co-Authors

Avatar

Morgana Moretti

Universidade do Extremo Sul Catarinense

View shared research outputs
Top Co-Authors

Avatar

Flávio Kapczinski

Universidade Federal do Rio Grande do Sul

View shared research outputs
Top Co-Authors

Avatar

Camila O. Arent

Universidade do Extremo Sul Catarinense

View shared research outputs
Top Co-Authors

Avatar

Luciano K. Jornada

Universidade do Extremo Sul Catarinense

View shared research outputs
Top Co-Authors

Avatar

Gabriel Rodrigo Fries

University of Texas Health Science Center at Houston

View shared research outputs
Top Co-Authors

Avatar

Amanda V. Steckert

Universidade do Extremo Sul Catarinense

View shared research outputs
Top Co-Authors

Avatar

Felipe Dal-Pizzol

Universidade Federal do Rio Grande do Sul

View shared research outputs
Top Co-Authors

Avatar

Roger B. Varela

Universidade do Extremo Sul Catarinense

View shared research outputs
Researchain Logo
Decentralizing Knowledge